{"name":"Parexel International","slug":"parexel","ticker":"Private","exchange":"Private (EQT)","domain":"parexel.com","description":"Parexel is an American contract research organization. It conducts clinical trials on behalf of its pharmaceutical and biotechnology clients to expedite drug development and clinical trial progress. It is one of the largest clinical research organizations in the world.","hq":"Durham, NC","founded":0,"employees":"","ceo":"Jamie Macdonald","sector":"CRO / Pharma Services","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$5B+ (private est.)","metrics":{"revenue":3000000000,"revenueGrowth":0.6,"grossMargin":0,"rdSpend":17800000,"netIncome":107300000,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Lipitor patent cliff ($10.4B at risk)","drug":"Lipitor","type":"patent_expiry","sentiment":"negative"},{"date":"2020-06-01","label":"Viagra patent cliff ($null at risk)","drug":"Viagra","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Parexel International Reports Fourth Quarter and Full Year 2023 Results","summary":"Parexel International reported its fourth quarter and full year 2023 results, with revenue increasing by 10% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2023-06-01","type":"deal","headline":"Parexel International Partners with Biotech Company to Develop New Cancer Treatment","summary":"Parexel International has partnered with a biotech company to develop a new cancer treatment, leveraging the company's expertise in clinical research and medical communications.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOa2ZScXRLdUdxSnZfTkNZSWZXaF9xSGpLOTJlMWwzSGx6OUZmblY1MG1zMDktWGpVYUZQb19yV1pJUHVRbXhJNnQybEYwQklGVVNMcmZwdG9FMFp5S3NKUDV6SXFuZkpYR2VYcFg0M3h5cGlLQ1RVeGpuMGZPMmpTTS1HelpiQQ?oc=5","date":"2025-12-16","type":"regulatory","source":"Fact.MR","summary":"Demand for RNA Therapy Clinical Trials in UK | Global Market Analysis Report - 2036 - Fact.MR","headline":"Demand for RNA Therapy Clinical Trials in UK | Global Market Analysis Report - 2036","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNd3Z2ZzNLX3hLVW5DQVNXeXpnYXVoQjZQWUhVLUdkZm1oLWROVU5kc0cyMnBNM1Myb1dpamVPaU1iZlhSdEpUMVdKMXBnZTJpTVJqaG1qa0cySkVwRzJXRTdWMVB6cnVCamtyRjFfTVlHQ0IySGZCQXduSzA0cDgwSkdYaXFaWHR1a0YxSWJrb3RmWFNMZFkyQg?oc=5","date":"2025-11-19","type":"pipeline","source":"BioSpace","summary":"CRO Boom in APAC Region, With China at the Forefront - BioSpace","headline":"CRO Boom in APAC Region, With China at the Forefront","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQMl9HSmdjOWFRMzJlaklyMUxTSnA5aVZlTHpaMEFTU2FGNXJYdVZCalNCcE0xTXJreUQ1MEotV0I4aVJTTUZJTDQ3SEt1MGxsQ0Z5Ul9tWVBaNVpYWUFuVzdZd0VOdkxvVFNVSmdaRUJmZmZIZTVpOXVtZjBTZXBxZDAwbkFCWUlVazdBZEZQbjBhc0NvcmY0TDJNY09SOTV2ZkZtNEtQdThQanVMUmpvTUNFa2lVSjh3WDhNd3JoVWwzczNydjhDWDFrNkZqLWFKMU1tanVWckNqdFpFSnRRZDFXcTJOUEZjS25BOWFFWWo1N0U?oc=5","date":"2025-09-08","type":"pipeline","source":"GlobeNewswire","summary":"Functional Service Provider (FSP) Market to Reach US$ 38.56 Billion by 2033 | Astute Analytica - GlobeNewswire","headline":"Functional Service Provider (FSP) Market to Reach US$ 38.56 Billion by 2033 | Astute Analytica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbzktb0ZpdUxHb0NIMGN5SjFBWG4zTjRCNmdqbHh4ZndyMjRfNHR6Yk1HNXpBVF93d1BlbzBNNGJfSXNNbnh4cGlxbFFiRmpwMmV4Vkd3WHJycDhfM1ZEZE1PcGVBb1htTVM0OW56cFBlZmVXV3FnZjdWcWtqZXV6aEY4RTFqODFNbUFfNVlOeW9kUm5BQUVhXzhudktUOWcxdUdWVlZtLVA?oc=5","date":"2025-08-06","type":"pipeline","source":"BioSpace","summary":"Big Pharma Provides Lifeline to Chinese Companies Struggling To Survive - BioSpace","headline":"Big Pharma Provides Lifeline to Chinese Companies Struggling To Survive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPVVFEaEJiT2JLNjRwSzg4YnNhUUt6YnFIN3RzaWdmZXlidFNiZlQ1YVNqWjVHWlppNkJtbXI2RUxyVWlXSWRYeDNpS1dVUkJ4Q1p2cGV0OUE4OGQ2cXMtYWs2Sk1Mckg0Y0IxLWpzaW5tRkFKQW85NFM2U21PWUxWaVRUWjRGRW04ekxxeUNZSWR6U255eTVtc21rclpmVnFyRWJGcmFQa1BlX0RfTDBJeFc1Z0hPamNBM2NXQ05TUHNPSG1aYlplUHZnSkxLVzBf?oc=5","date":"2025-02-26","type":"trial","source":"Reuters","summary":"India on the verge of becoming clinical trials hub, Parexel executive says - Reuters","headline":"India on the verge of becoming clinical trials hub, Parexel executive says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOS01WX1JFQ1BZTGZ4THpZaW5aNzljSTFKcnBGLWpMQUVzQVhjeXEyVXEzdFZIT0hldkFCZXlhLXNvSEl4bXJzQ2hkWk9zZ2ZrY01ORXd3VXZjdFR6ZDh1MEdhX1o3RFlhLVVOSkY3MmEtZ0NRTmJ2SVh0NmpZYXJKeXdDdnJfekJmM3dR?oc=5","date":"2024-12-03","type":"pipeline","source":"Yahoo Finance","summary":"Pharmaceutical CRO Market Report 2025-2030, Featuring Parexel, ICON, Laboratory Corporation of America, Thermo Fisher Scientific, Medpace, IQVIA, WuXi AppTec and Veeda Clinical Research - Yahoo Financ","headline":"Pharmaceutical CRO Market Report 2025-2030, Featuring Parexel, ICON, Laboratory Corporation of America, Thermo Fisher Sc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPTkZSUk9WZDdPMkFveW56V0ExbWd5ck1LWWlkelNTY1JJUFpvMDlCN2d2dVVsd25wVnpnbVJhMWRXeThCdEpJZ01nelFQdG1NeG9SVFktS2lUMlZ6bk1aUzlZcW5FbGtwZjg2LVhzWG5ZS096WXFHcExmRTRMLUVSOW5sMnMwUU5BSEU4V2p5d1g1Y2E2eXdMWU1R?oc=5","date":"2024-09-03","type":"pipeline","source":"Axios","summary":"North Hills Innovation District lands first pharmaceutical tenant in Parexel - Axios","headline":"North Hills Innovation District lands first pharmaceutical tenant in Parexel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPaWpSZENEVi1vcG1EWXp5bUtFX3ZiSkFSMVpjZlo4el9iZmR5VS1SVGFGNUxQU0tjVEtwNUZIMm5tdWJhZER4eFNGcHN5VHFlWG8tZC1yWlhWWTB4Y21sdlNvRzZxbGpnUGFVUVk1V2NfaC1XMm9rT083ZlN0WGtEeVQwSnZXN2dldlJqajhxZWdZMXM?oc=5","date":"2023-10-27","type":"pipeline","source":"Pharma Voice","summary":"Red Jacket: Dr. Mark Goldberg, a clinical innovator - Pharma Voice","headline":"Red Jacket: Dr. Mark Goldberg, a clinical innovator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPUXNMYVZiZHNHYUxkbzBRZWtOOEhJVUlMY1BVRVRXZHRJVV9Ed2hHc05lMHp3d3pxdHVuLXpNbG16bi1ydlpTWHlKRUd5aUdnUXlZUnFiZnpBRVJOcE5KTWFOLWUtM05mWExLcG9KckV2Z1RVRVBGM29jZzllNXhIaGpWb0ZvZw?oc=5","date":"2022-12-02","type":"trial","source":"kffhealthnews.org","summary":"The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice. - kffhealthnews.org","headline":"The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPaEwtRzVSaElNUmViUy01a0R1QU9tb254S000blF3T2E5RDMzVW9KN0h2VXpTMkViMWZQMU91cFR4TmFiQlpVLTBMWE1SeVJHVjBjMnl4NG42UzdFejJIZDNBbUhDOHQ4WHVVd2RONThiYkpnamF5cC1FWXNubGhvcG80SmUteEJnRVBDcFN5QWZ6R1pUSVhybE1DQkJnWmVLUjROeDJ4NFFDdlVILUVqSi1nOFczUDBId2QzanN0VnNlV2MyVXN3SkF0cnQtWEJtcWpNSWFR?oc=5","date":"2021-07-02","type":"deal","source":"Cision News","summary":"EQT Private Equity and Goldman Sachs Asset Management to acquire Parexel, a leading global clinical research organization, for USD 8.5 billion - Cision News","headline":"EQT Private Equity and Goldman Sachs Asset Management to acquire Parexel, a leading global clinical research organizatio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQRnZpY0Zfbkp5UnpJbVFTUFBDUjdFQ05xMWZ0RWFyVU1wSVluaTNPWnBzNGpWaFZDNGtpUzZfQWlzc0p2TGkyRzZKNDFVaXB6Nk93cXM2dm9DY1NaXy1CVV9LaTNscDQzeEFvMVdiSy1PTThzVUduX3ZhVnR3LVJkVVpEc0swdjhNR3FUdXYzNjhpTG5Bb1hlWmhxZmlJd0E?oc=5","date":"2021-07-02","type":"pipeline","source":"MedCity News","summary":"CRO Parexel changes private equity hands again, this time for $8.5B - MedCity News","headline":"CRO Parexel changes private equity hands again, this time for $8.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOVU9qOW9BdHVUbE5xamJzQXcwMGM3amU0YnpDRnBIdUV0UjVSOXY3eDJPME5zZEdTZGI4LU5mc0NkR3E0QnpCNWw3QkZOZ0dyRUY0cGw2Qjg0cktpTWs4U3MyZTF2bFVPYmlwd1E0d0VSYnl3UlRXa1p1bkZDZXRPbjdfZDU0M2M0bDFsek5tQm1RNFY3d21LcEFR?oc=5","date":"2017-06-21","type":"pipeline","source":"BioPharma Dive","summary":"Private equity firm snaps up Parexel - BioPharma Dive","headline":"Private equity firm snaps up Parexel","sentiment":"neutral"}],"patents":[{"drugName":"Viagra","drugSlug":"sildenafil","patentNumber":"","type":"Patent Cliff","expiryDate":"2020-06-01","territory":"US"},{"drugName":"Lipitor","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":10400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["IQVIA","LabCorp","Icon plc"],"therapeuticFocus":["Oncology","Infectious Diseases","Rare Diseases"],"financials":{"source":"sec_edgar","revenue":2441500000,"revenuePeriod":"2017-06-30","revenueHistory":[{"value":2441500000,"period":"2017-06-30"},{"value":2426300000,"period":"2016-06-30"},{"value":2426300000,"period":"2016-06-30"},{"value":2330274000,"period":"2015-06-30"},{"value":2330300000,"period":"2015-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":17800000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":107300000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}